Sun Pharmaceutical Industries Ltd. announced on Friday it gained permission from Drugs Controller General of India to begin a clinical trial for COVID-19 treatment with Nafamostat Mesilate.
Nafamostat, an anticoagulant employed to treat acute pancreatitis, has been approved for human use in Japan and South Korea for over a decade.
Clinical trials of the drug have already started in Germany and the Netherlands.
By:Mohamed Ben Abderrazek Senegal places itself as Tunisia's leading trading partner in sub-Saharan Africa, earning…
The seismic monitoring stations of the National Institute of Meteorology registered an earthquake this Wednesday,…
Slovak Prime Minister Robert Fico is currently undergoing surgery and his condition is "extremely serious,"…
“Al-Hamaizia” region of the Al-Amra delegation in the governorate of Sfax saw this evening, Wednesday,…
The Minister of Agriculture, Water Resources and Fisheries, Abdel Moneim Belaati, stated that he was…
The culprits were vigorously sought within National Television (Wataniya) and they will pay dearly. I…
This website uses cookies.